Clinical Trials

    Showing 1 - 10 of 10 Digestive System Diseases

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Alison Clayton

    Phone: 346.238.7169

    This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.... Read more >

    Status: Enrolling

    Investigator: Abhishek Kansara

    Study Coordinator: Steven Puckitt

    Phone: 346.238.4586

    This research study is designed to evaluate the safety and effectiveness of the ReCET™ device for improving glycemic (blood sugar) control in individuals with T2D. This study plans to enroll a minimum of 264 and a maximum of 350 participants from ... Read more >

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Alison Clayton

    Phone: 346.238.7169

    Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ can... Read more >

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Nicole Barrios

    Phone: 713.441.5607

    The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >

    Status: Enrolling

    Investigator: Jian Guan

    Study Coordinator: Nicole Barrios

    Phone: 713.441.5607

    Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocard... Read more >

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolizatio... Read more >

    Status: Open Not Enrolling

    Investigator: Abhishek Kansara

    Study Coordinator: Steven Puckitt

    Phone: 346.238.4586

    This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of plozasiran injection in approximately 1328 adult subjects with HTG. After informed consent, subjects will be assessed for eligib... Read more >

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, an... Read more >

    Status: Enrolling

    Investigator: Kevin Tran

    Study Coordinator: Nicole Barrios

    Phone: 713.441.5607

    This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options inc... Read more >

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Rebecca Hildebrandt

    Phone: 713.441.0528

    This Phase II clinical trial at Houston Methodist Neal Cancer Center is evaluating the safety and efficacy of combining 5-Fluorouracil (5FU) -based chemotherapy (either FOLFIRI: folinic acid, 5FU, irinotecan; or mFOLFOX6: folinic acid, 5FU, oxaliplat... Read more >